Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of :

► Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence

► Prostate and Bladder Cancers

We have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas.

Our objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization.

Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development.

Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC.